Under-eating on GLP-1s: real risk or TikTok panic?

What did @drjonesdc actually say?

The core argument here is that GLP-1 users hit a weight loss plateau because they eat too little for too long. Dr. Jones DC, who identifies as a DC (Doctor of Chiropractic), not a medical doctor, says the medications suppress appetite so effectively that patients "have to freaking remember to eat when you're not hungry." His fix: eat more, do mindset training, and contact his clinics. The pitch is wrapped in genuine clinical observation, but it slides quickly into a service promotion.

The claim about under-eating causing a plateau is not invented. It reflects a real pattern clinicians see. The framing around "starvation mode" and metabolic downregulation, though, is where things get slippery. Let's pull it apart.

Does the science back this up?

Partially, yes. Severe caloric restriction does reduce resting metabolic rate. A landmark study by Rosenbaum and Leibel (2010, New England Journal of Medicine) showed sustained caloric deficit triggers adaptive thermogenesis, the body burns fewer calories at rest. This is real. But the term "starvation mode" oversimplifies a spectrum of metabolic adaptation that varies significantly by degree of restriction and individual physiology.

On GLP-1s specifically, semaglutide and tirzepatide trials (STEP 1, SURMOUNT-1) did not show plateau caused primarily by caloric under-restriction. Plateaus in those trials were multifactorial: dose ceiling effects, lean mass loss, and reduced non-exercise activity thermogenesis (NEAT). A 2022 analysis by Wilding et al. (Diabetes, Obesity and Metabolism) noted that weight regain after discontinuation partly reflects lean mass loss during treatment, which is a separate problem from just eating too little.

The idea that eating more protein and adequate calories preserves lean mass during GLP-1 therapy is supported. Cava et al. (2017, Advances in Nutrition) confirmed that protein adequacy during caloric restriction attenuates muscle loss. That part of the underlying logic holds.

What did they get wrong (or right)?

Credit first: the observation that patients swing from years of overeating to dramatic under-eating on GLP-1s is clinically documented and underappreciated on social media. The psychological flip, trading food obsession for forgetting to eat entirely, is real and worth flagging to patients.

What's wrong: calling it "starvation mode" without qualification is sloppy. It implies a binary switch that doesn't exist. Metabolic adaptation is gradual and dose-dependent. Telling patients they "turn into a freaking zombie" because of under-eating conflates several distinct issues: micronutrient deficiency, protein insufficiency, and actual adaptive thermogenesis. These have different solutions.

Bigger problem: Dr. Jones DC is a chiropractor. His title "holistic obesity expert" is self-assigned, not a recognized credential. Using "Dr." on a health platform without clarifying that credential is a disclosure gap that matters when the advice ends with "shoot us a text message" to join paid clinics. The advice may not be harmful in this clip, but the framing deserves scrutiny.

What should you actually know?

If you are on semaglutide or tirzepatide and have stalled, under-eating is one possible contributor, not the only one. The more important variables are protein intake, resistance training, sleep quality, and whether your current dose has reached its pharmacological ceiling. A 2023 review by Ghusn et al. (Obesity Pillars) found that incorporating structured resistance exercise during GLP-1 therapy significantly preserved lean body mass compared to caloric restriction alone.

Protein targets during GLP-1 therapy are generally cited at 1.2 to 1.6 grams per kilogram of body weight per day, based on guidelines from the European Society for Clinical Nutrition and Metabolism. That is the actionable number behind the vague "eat more" instruction.

If you are experiencing brain fog, fatigue, and constipation on these medications, talk to a licensed prescriber, not a text line linked in a TikTok bio. Those symptoms can reflect GI side effects of the medication itself, not just caloric restriction.